

CE-IVD received for STI test

Genetic Signatures Limited (ASX: GSS, “**Genetic Signatures**” or the “**Company**”) is pleased to advise that it has received CE-IVD registration for its **3base™ EasyScreen™** STI Genital Pathogen Detection Kit, which can detect 10 of the most commonly encountered sexually transmitted infections (STI’s) simultaneously. CE-IVD allows the kit to be marketed freely in the European Union and the UK.

John Melki, Genetic Signatures CEO, said, “*This is the 5th 3base™ EasyScreen™ Detection Kit to attain CE-IVD registration, a significant achievement as we continue to execute on our global expansion strategy. Sexually transmitted infections (STI’s) are a large and growing problem globally, and we are pleased to be able to provide a high throughput and accurate diagnostic solution to improve patient outcomes.*

Our Company continues to work on new products and enhancing current product offerings even while we meet the substantial demand for our EasyScreen™ SARS-CoV-2 Detection Kits”.

STI’s can have a significant impact on sexual and reproductive health. There are an estimated 1 million STI’s contracted daily around the world, and the 4 most commonly reported infections (*Chlamydia*, *Gonorrhoea*, Syphilis and *Trichomoniasis*) account for approximately 376 million cases per annum¹. The global testing market value is estimated to be US\$420m pa just for *Chlamydia* and *Gonorrhoea*², and forecast to grow at 7% p.a.

An application for TGA registration was lodged late last year also, and this clearance is anticipated soon.

For further information, see our website (www.geneticsignatures.com) or contact us as below:

Dr John Melki

Chief Executive Officer

john.melki@geneticsignatures.com

T: +61 (0)2 9870 7580

Peter Manley

Chief Financial Officer

peter.manley@geneticsignatures.com

Announcement authorised by Genetic Signatures’ Board of Directors

About Genetic Signatures Limited: Genetic Signatures is a specialist molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary platform technology, **3base™**. Genetic Signatures designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the **EasyScreen™** brand. Genetic Signatures’ proprietary MDx **3base™** platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures’ current target markets are major hospital and pathology laboratories undertaking infectious disease screening.

¹ [https://www.who.int/en/news-room/fact-sheets/detail/sexually-transmitted-infections-\(stis\)](https://www.who.int/en/news-room/fact-sheets/detail/sexually-transmitted-infections-(stis))

² Kalorama Information, Molecular Testing Markets for Infectious Diseases (Sepsis, Respiratory Diseases, HIV, Hepatitis, TB Testing, STIs and Other Tests), July 2019